Latest News Feed

Press Release Oct 6, 2026
Belhaven Biopharma Initiates Pivotal Study of BBP01, a Nasal Powder Formulation of Epinephrine to Treat Anaphylaxis

Randomized crossover trial will compare the pharmacokinetics and pharmacodynamics of intranasal epinephrine powder against intramuscular auto-injector and manual injection in healthy participants
Press Release Jul 16, 2026
Belhaven Announces Significant Expansion of Nasdepi Patent Portfolio, Commercial Supply Readiness, and FDA Alignment on Key Topics

Pivotal Clinical Study Poised to Start in Q3 2026
Press Release Oct 8, 2025
Belhaven Biopharma Initiates a Pivotal Biocomparability Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Nasdepi(R) vs. Epinephrine Intramuscular Injections

Belhaven's Investigational New Drug (IND) Application Receives FDA Authorization to Proceed
Press Release Aug 19, 2025
Belhaven Biopharma Closes Oversubscribed Series a to Fund the Development of Nasdepi(R) Program Moves Into Late Stage Clinical and Manufacturing Through NDA Approval

Accelerated Round Completion Positions Company for New Drug Application (NDA) Submission and Commercial Launch Partnerships
Press Release Apr 15, 2025
Belhaven Biopharma Announces Positive Data From Their Nasdepi(R) Dose Confirmation Study in Patients With and Without Allergic Rhinitis

Study Confirms Nasdepi® Dose Enabling Pivotal Biocomparability Study and Commercial Manufacturing
Press Release Jan 21, 2025
Belhaven Biopharma Raises $11M to Advance Nasdepi(R): The Dry Powder Nasal Breakthrough for Anaphylaxis

Oversubscribed Seed Round Accelerates Nasdepi®'s Journey as the First Dry Powder Nasal, Heat-Stable Treatment for Anaphylaxis
Press Release Dec 11, 2024
Belhaven Biopharma Set to Unveil Promising Nasdepi(R) Data at DDL 2024

Dry Powder Epinephrine Product Demonstrates Reliable and Consistent Delivery in Real-World Dosing Situations with a Heat-Stable Formulation
Belhaven Biopharma to Present Promising Phase 1 Data on Needle-Free Epinephrine Powder at ACAAI Annual Meeting
Press Release Oct 24, 2024
Belhaven Biopharma to Present Promising Phase 1 Data on Needle-Free Epinephrine Powder at ACAAI Annual Meeting

Phase 1 results demonstrate rapid absorption and response profile, highlighting Nasdepi® as an innovative alternative for emergency allergy treatment
Press Release Oct 22, 2024
Belhaven Biopharma’s Nasdepi® Named Finalist for 2024 Fierce Innovation Awards in Drug Delivery Technology

Nasdepi® Recognized for Revolutionizing Emergency Allergy Treatment with Needle-Free, Rapid-Acting Dry Powder Drug Delivery